Alzheimer's Drug Discovery Foundation

Investment and grant decisions are led by Co-Founder and Chief Science Officer Dr. Howard Fillit, a board-certified geriatrician and neuroscientist. Dr. Fillit joined the Lauder brothers in founding ADDF in 1998 and oversees the scientific review process. Final funding authority rests with the board, co-chaired by Leonard and Ronald Lauder.

ADDF sources opportunities through a global network of academic medical centers, biotech incubators, and direct relationships with researchers in over 20 countries. The foundation's Diagnostics Accelerator, co-funded by Bill Gates, Jeff Bezos, and MacKenzie Scott, operates as a separate inbound channel for biomarker and diagnostic-platform investments. ADDF's chief science officer and scientific review board also maintain active conference and publishing presences that generate referrals.

ADDF primarily makes direct grants and mission-related equity investments into individual drug-discovery companies and academic programs. The foundation has not publicly disclosed commitments to traditional venture capital funds as a limited partner, maintaining a predominantly direct investment posture consistent with its venture philanthropy model.

ADDF targets the earliest stages of drug development — seed, start-up, and early venture rounds — explicitly filling the translational gap between laboratory discovery and clinical trials. The foundation's grants and equity investments support Investigational New Drug (IND)-enabling studies, Phase I safety trials, and early proof-of-concept clinical work in Alzheimer's disease and related dementias.

ADDF was initially capitalized by Leonard and Ronald Lauder, whose wealth derives from The Estée Lauder Companies — the publicly traded cosmetics conglomerate their mother founded. The foundation has since diversified its funding base to include major technology philanthropists, with Jeff Bezos, MacKenzie Scott, and Bill Gates all co-funding the Diagnostics Accelerator initiative alongside the Lauders' contributions.

Yes. ADDF operates as a 501(c)(3) nonprofit under U.S. tax law, with its traditional grant-making arm legally distinct from any mission-related equity investments. The Diagnostics Accelerator is housed within ADDF and functions as a dedicated philanthropic initiative, co-funded by multiple external donors, rather than through a separate for-profit vehicle.

ADDF has no formal corporate relationship with The Estée Lauder Companies, but its founding capital originated from the Lauder family's Estée Lauder fortune. Leonard A. Lauder serves as Chairman Emeritus of the cosmetics company and his brother Ronald S. Lauder is Chairman of Clinique Laboratories — both Estée Lauder subsidiaries. The Lauder family's philanthropic network provides ongoing fundraising access, but ADDF operates independently from the corporate entity.